MCL1/CDK9 screen published in eLife

Our CRISPR screening projects are starting to come out! Today work from postdoc Shaheen Kabir, in collaboration with oncologists at AstraZeneca, was published in eLife. Shaheen used a very creative FACS screen to find genes involved in the early apoptotic response to CDK9 and MCL1 inhibitors. Inhibition of CDK9 reduces transcript half-life and indirectly inhibits MCL1, whereas the other compound screen directly binds MCL1. Several cancers respond well to these new compounds, but others are already completely resistant. Shaheen went looking for genes involved in this resistance and found some very interesting shared hits. She focused her mechanistic work on the CUL5 ubiquitin ligase complex, which is a multi-component system used to degrade target proteins. Almost every component of the CUL5 complex was a hit in the screen, and Shaheen found that knockdown of CUL5 components affected the stability of pro-apoptotic proteins Bim and Noxa. CUL3 type ligases are already established cancer targets, and Shaheen’s work shows that CUL5 could also be targeted to synergize with front-line cancer therapeutics. Congratulations Shaheen!

SUBMIT A COMMENT

Your email address will not be published.

Filters

Latest News

March 15, 2022

Welcome to Martina

Martina received her BSc degree in Biochemistry at the Imperial College London, graduating in July 2020. She joined the Corn Lab in February 2022 and her Master...

March 15, 2022

Welcome to Simone

Simone received his Bachelor’s degree in Biotechnology in 2020, from the Università del Piemonte Orientale, Novara, Italy. He joined the Corn Lab in July ...

March 15, 2022

Welcome to Sam

Sam received his Bachelor’s degree in Health Science and Technology from ETH Zürich in 2021. He joined the Corn Lab as a Master student in May 2021 working on ...

News Archive

Tweets